By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regulus Therapeutics, Inc. 

1896 Rutherford Road

Carlsbad  California  92008-7208  U.S.A.
Phone: 888-734-8587 Fax: n/a


Start Up

Company News
Regulus (RGLS) Completes RG-101 Enrollment In Phase II Combination Study 1/21/2016 6:27:53 AM
Regulus (RGLS) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 1/7/2016 7:00:15 AM
Regulus (RGLS) Release: RG-125(AZD4076), A microRNA Therapeutic Targeting microRNA-103/107 Being Developed For The Treatment Of NASH In Patients With Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development 12/18/2015 6:52:43 AM
Regulus (RGLS) Appoints Joseph P. Hagan Chief Operating Officer 12/7/2015 8:56:12 AM
Regulus (RGLS) Announces Grant Of Patents Covering Lead microRNA Therapeutics 11/12/2015 4:36:13 PM
Regulus (RGLS) Reports Third Quarter 2015 Financial Results And Recent Highlights 11/6/2015 7:19:07 AM
Regulus (RGLS) Expands Development Of RG-101 Through Clinical Trial Collaboration With GlaxoSmithKline (GSK) 11/3/2015 6:54:24 AM
Regulus (RGLS) Announces Timing For Third Quarter 2015 Financial Results Webcast And Conference Call 10/30/2015 6:33:48 AM
Regulus (RGLS) Achieves All Research Milestones In Collaboration With Biogen (BIIB) To Identify microRNA Biomarkers For Multiple Sclerosis 10/28/2015 7:42:17 AM
Regulus (RGLS) To Present Additional Preclinical Data Supporting RG-012 As A Novel microRNA Therapeutic In Development For Alport Syndrome At American Society of Nephrology's Kidney Week 2015 10/6/2015 7:03:53 AM